A randomized, double-blind, double dummy, placebo-controlled, four-way cross-over study to investigate the analgesic effects and CNS effects of morphine and fluvoxamine in healthy subjects.

2023-505793-15-00 Human pharmacology (Phase I) - Other Ended

Start 30 Oct 2023 · End 3 May 2024 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 24
Countries 1
Sites 1

Chronic pain

Key facts

Sponsor
Centre for Human Drug Research
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
30 Oct 2023 → 3 May 2024
Decision date (initial)
2023-10-27
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Chronic pain

VersionLevelCodeTermSystem organ class
20.1 LLT 10049475 Chronic pain 10018065

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre for Human Drug Research

Sponsor organisation
Centre for Human Drug Research
Address
Zernikedreef 8
City
Leiden
Postcode
2333 CL
Country
Netherlands

Scientific contact point

Organisation
Centre for Human Drug Research
Contact name
Principal investigator

Public contact point

Organisation
Centre for Human Drug Research
Contact name
Principal investigator

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 24 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Centre for Human Drug Research
Pain, Zernikedreef 8, 2333 CL, Leiden

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2023-10-30 2024-05-03 2023-11-01 2024-05-03

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-09-04 Netherlands Acceptable
2023-10-27
2023-10-27
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-02-29 Netherlands Acceptable
2023-10-27
2024-02-29